Topic index / Joint Procurement Office for National Centralized Drug Procurement / Full chronicle

Joint Procurement Office for National Centralized Drug Procurement · Full chronicle and history

2026-06-09

National Drug Procurement Office Reports Serious Defects in Production Line of Centrally Procured Drug Amiodarone Hydrochloride Injection; Production Suspended

On June 9, 2026, the National Organization for Joint Drug Procurement announced that the production line for amiodarone hydrochloride injection, a centrally procured life-saving drug produced by Shandong Beida Gaokua Huatai Pharmaceutical, has serious defects and has been ordered to suspend production.

Location: Shandong · Importance III · Verification: Official claim · View causal chain →